FOLLOWUS
Effects of salivae miltiorrhizae liguspyragine hydrochloride and glucose injection (参芎葡萄糖注射液) on the levels of main platelet thrombin receptors in chronic haemodialysis patients
- Chinese Journal of Integrative Medicine Vol. 17, Issue 8, Pages: 625-630(2011)
- Affiliations：
Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 30572441)
DOI：10.1007/s11655-011-0826-8
CLC：Published：2011，
Published Online：9 August 2011，
Scan for full text
Li, Y., Shen, L., Chen, R. et al. Effects of salivae miltiorrhizae liguspyragine hydrochloride and glucose injection (参芎葡萄糖注射液) on the levels of main platelet thrombin receptors in chronic haemodialysis patients., Chin. J. Integr. Med. 17, 625 (2011). https://doi.org/10.1007/s11655-011-0826-8
Yan Li, Lin Shen, Rui Chen, et al. Effects of salivae miltiorrhizae liguspyragine hydrochloride and glucose injection (参芎葡萄糖注射液) on the levels of main platelet thrombin receptors in chronic haemodialysis patients. [J]. Chinese Journal of Integrative Medicine 17(8):625-630(2011)
Li, Y., Shen, L., Chen, R. et al. Effects of salivae miltiorrhizae liguspyragine hydrochloride and glucose injection (参芎葡萄糖注射液) on the levels of main platelet thrombin receptors in chronic haemodialysis patients., Chin. J. Integr. Med. 17, 625 (2011). https://doi.org/10.1007/s11655-011-0826-8 DOI：
Yan Li, Lin Shen, Rui Chen, et al. Effects of salivae miltiorrhizae liguspyragine hydrochloride and glucose injection (参芎葡萄糖注射液) on the levels of main platelet thrombin receptors in chronic haemodialysis patients. [J]. Chinese Journal of Integrative Medicine 17(8):625-630(2011) DOI： 10.1007/s11655-011-0826-8.
摘要
To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection (参芎葡萄糖注射液
SLGI) on the expression of platelet membrane receptors proteinase-activated receptor-1 (PAR1) and proteinase-activated receptor-4 (PAR4) in end-stage renal disease (ESRD) patients on chronic haemodialysis (HD). Eighty-six ESRD patients on HD (treated group) were treated with SLGI
7 days as one therapeutic course
for two successive courses. The previous therapies were unchanged. Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients
and turbidity method was used to determine the platelet maximum aggregation rate (MAR). Meanwhile
renal function was measured. The final data were compared with those before treatment and with those in the normal control group (54 healthy subjects). Compared with the normal control group
the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment (P=0.001
P=0.006
and P=0.008); after treatment with SLGI
the above indices in patients were remarkably decreased (P=0.036 and P=0.046)
except PAR4 (P=0.067)
but still higher than those in the normal control group
however
it was not statistically significant. (1) The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD. (2) SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD
improve platelet function
and regulate platelet activation.
Abstract
To investigate the effects of Salvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection (参芎葡萄糖注射液
SLGI) on the expression of platelet membrane receptors proteinase-activated receptor-1 (PAR1) and proteinase-activated receptor-4 (PAR4) in end-stage renal disease (ESRD) patients on chronic haemodialysis (HD). Eighty-six ESRD patients on HD (treated group) were treated with SLGI
7 days as one therapeutic course
for two successive courses. The previous therapies were unchanged. Flow cytometry was used to assess the expression of platelet PAR1 and PAR4 in the patients
and turbidity method was used to determine the platelet maximum aggregation rate (MAR). Meanwhile
renal function was measured. The final data were compared with those before treatment and with those in the normal control group (54 healthy subjects). Compared with the normal control group
the expressions of PAR1 and PAR4 and platelet MAR in ESRD patients on HD was significantly higher before treatment (P=0.001
P=0.006
and P=0.008); after treatment with SLGI
the above indices in patients were remarkably decreased (P=0.036 and P=0.046)
except PAR4 (P=0.067)
but still higher than those in the normal control group
however
it was not statistically significant. (1) The overexpression of PAR1 and PAR4 might lead to increased platelet aggregation and this could be one of the reasons for the thrombotic events in ESRD patients on HD. (2) SLGI was able to down-regulate the expression of PAR1 in ESRD patients on HD
improve platelet function
and regulate platelet activation.
关键词
end-stage renal diseasechronic haemodialysisplatelet thrombin receptorsSalvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection
Keywords
end-stage renal diseasechronic haemodialysisplatelet thrombin receptorsSalvia Miltiorrhiza Liguspyragine Hydrochloride and Glucose Injection
references
Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30:579–589.
Li Y, Shen L, Chen R, Lu FR, Li J, Liu JG. Levels of main platelet thrombin receptors in older chronic haemodialysis patients. Chin Med J 2010;123:2495–2496.
Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003;18:1834–1841.
Wang HY, eds. Nephropathy. 2nd ed. Beijing: People’s Medical Publishing House; 1996:1385.
Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol 1990;52:431–449.
Wyant TL, Smith PC, Brown B, Kantor AB. Whole blood microvolume laser scanning cytometry for monitoring resting and activated platelets. Platelets 2001;12:309–318.
Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758–763.
Qin Y, Shen L, Lu FR, Shi W, Liu JG. Effect of Xiaoyu Zhixue Tablet on the expression of platelet membrane glycoprotein Ib/IX/V complex in patients with chronic renal failure. Chin J Integr Med 2008;14:83–87.
Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986;108:246–252.
Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988;85:806–810.
Zwaginga JJ, MJ IJ, de Groot PG, Vos J, de Bos Kuil RL, Sixma JJ. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb 1991;11:733–744.
Benigni A, Livio M, Dodesini P, Schieppati A, Panigada M, Mecca G, et al. Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated? Am J Nephrol 1985;5:243–247.
Kyrle PA, Stockenhuber F, Brenner B, Gossinger H, Korninger C, Pabinger I, et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. Thromb Haemost 1988;60:205–208.
Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000;39:5458–5467.
Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000;275:25216–25221.
Diaz-Ricart M, Estebanell E, Cases A, Calls J, Lopez-Pedret J, Carretero M, et al. Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling. Kidney Int 2000;57:1905–1914.
Yang HX, Jiang HB. Clinical observation of combination of Danshen and Chuanxiongqin Injection and Astragali Injection in patients with stable angina pectoris. J Hunan Environ Biol Polytechnic (Chin) 2008;14(3):7–9.
Li S, Wan L. Experimental study on the preventive mechanism of Salviae Miltiorrhizae against atherosclerosis in rabbits models. J Huazhong Univ Sci Technol Med Sci 2004;24:233–235.
Wang Yan, Li Yan. Efficacy of Asparagine Hydrochloride and Glucose Injection on ischemic colitis. Chin J Gastroentero Hepatol (Chin) 2009;18: 646–648.
Che XW, Zhang Y, Wang H, Wang W. Effect of ligustrazine injection on levels of interleukin-4 and interferon-gamma in patients with bronchial asthma. Chin J Integr Med 2008;14:217–220.
0
Views
825
Downloads
11
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
